Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
Colson AE, Kumar PN, Ruane PJ, Chetchotisakd P, Ratanasuwan W, Liberty A, Nahass RG, Arenas-Pinto A, Post FA, Baker DA, Cahn P, Hofmann E, Watanabe D, Lu PL, Roukens AHE, Parczewski M, Wang H, Chen K, Shihadeh F, Shaughnessy M, Dvory-Sobol H, SenGupta D, Llamoso C, Rhee M, Ogbuagu O; ISLEND-2 Study Team.
Colson AE, et al.
Lancet. 2026 Aug 29;408(10557):821-832. doi: 10.1016/S0140-6736(26)01442-X. Epub 2026 Aug 12.
Lancet. 2026.
PMID: 42586113
Clinical Trial.